Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW to Strengthen Measures Against Improper Research Practices from FY2014; Surprise Inspections Also Planned
October 1, 2013
- Health Ministry Approves Sovriad, Hizentra
September 30, 2013
- Incentives to Promote the Use of Generic Drugs by DPC Hospitals Being Discussed: Director Utsunomiya of MED
September 30, 2013
- TPP Partners Likely to Accept Japanese Proposal on Data Exclusivity Period: Mr Eto of LDP
September 30, 2013
- Japan Health Minister Meets Exec of Swiss Novartis, Seeks Cooperation in Diovan Probe
September 27, 2013
- Global Simultaneous Development Likely to Expand with Premium for New Drug Development: PhRMA
September 27, 2013
- CSIMC Subcommittee Recommends Addition of Consumption Tax to Actual Market Prices, Will Continue Discussing Method for Clearly Specifying Added Tax
September 27, 2013
- JPWA Seeks Generic Name Listing for Wider Range of Generics
September 27, 2013
- FPMAJ Opposes Removing Exceptions for 80% Pricing Rule for Racemic Body-Derived Drugs
September 26, 2013
- Mixed Healthcare Using Unapproved Drugs Proposed for Special Zone
September 26, 2013
- Health Ministry Approves 28 Products including Oblean, Kadcyla
September 26, 2013
- Discussions on Reform of the High-cost Healthcare Benefit System on the Horizon; Will It Be Possible to Reduce Drug Copayments?
September 25, 2013
- Japan Needs Generic Drug Makers that Can Compete in the Global Market: Director Jo of EAD
September 25, 2013
- Regulatory Reform Council Sets Out Policies to Monitor Ministries’ Deregulation Efforts
September 24, 2013
- MHLW to Introduce E2B (R3) Format in April 2016
September 24, 2013
- FTC’s Legal Intervention in Diovan Issue Possible, but Only with New Facts: Lawyer
September 20, 2013
- MHLW Requests Revision of Package Inserts for Losartan, Celecoxib, 9 Other Drugs
September 19, 2013
- MHLW Plans to Establish Ethics Committee Certification System to Improve the Quality of Clinical Research
September 18, 2013
- Diovan Scandal Undermined National Interests, Health Ministry Official Says
September 18, 2013
- Director Jo of EAD Urges Drug Makers to Go on the Offensive
September 18, 2013
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…